00:25 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Avanir begins Phase II trial of AVP-786 for neurobehavioral disinhibition from TBI

The Avanir Pharmaceuticals Inc. subsidiary of Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral AVP-786 (CTP-786) for up to 12 weeks in about 150 patients...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

AVP-786: Phase III started

Otsuka began the double-blind, placebo-controlled, U.S. Phase III TRIAD-1 trial to evaluate 2 doses of oral AVP-786 twice daily for 12 weeks in about 380 patients. The start of the trial triggered a $2 million...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

AVP-786: Phase II started

Avanir began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral AVP-786 for 10 weeks in about 200 patients with MDD who had an inadequate response to antidepressant treatment, including selective serotonin reuptake...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

Dextromethorphan/quinidine: Completed Phase II enrollment

Avanir completed enrollment of 220 patients in the double-blind, placebo-controlled, U.S. Phase II AVR-131 trial to evaluate 20/10 and 30/10 mg oral dextromethorphan/quinidine twice daily for 10 weeks. Top-line data are expected in late September...
01:23 , Feb 14, 2014 |  BC Extra  |  Financial News

Concert raises $84 million in IPO

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) raised $84 million in an IPO through the sale of a bumped-up number of shares at the high end of its proposed range. The company sold 6 million shares at $14,...
01:02 , Feb 4, 2014 |  BC Extra  |  Financial News

Concert sets IPO terms

Concert Pharmaceuticals Inc. (Lexington, Mass.) amended its IPO and said it now plans to sell 5 million shares at $12-$14. At the $13 midpoint, the company -- which is seeking to list on NASDAQ --...
02:02 , Jan 14, 2014 |  BC Extra  |  Financial News

Concert, Microlin Bio file for IPOs

Concert Pharmaceuticals Inc. (Lexington, Mass.) and Microlin Bio Inc. (New York City, N.Y.) both filed for IPOs on NASDAQ. Concert filed to raise up to $74.8 million in an IPO underwritten by UBS; Wells Fargo;...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

Nuedexta dextromethorphan/quinidine: Phase II data

Top-line data from the double-blind, placebo-controlled, international Phase II PRIME trial in 209 MS patients with central neuropathic pain showed that twice-daily AVP-923 missed the primary endpoint of reducing Numeric PRS scores from baseline to...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

AVP-923: Completed Phase II enrollment

Avanir completed enrollment in the double-blind, placebo-controlled, international Phase II PRIME trial evaluating 45/10, 30/10 and 20/10 mg AVP-923 twice daily for 12 weeks. In February, the company said it would reduce target enrollment in...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

AVP-786: Phase I data

Data from 36 healthy volunteers in the first stage of a double-blind, crossover Phase I trial showed that AVP-786 plus low-dose quinidine had a comparable pharmacokinetic, safety and tolerability profile to that of AVP-923 ,...